SOURCE: Herborium Group, Inc.

June 09, 2009 08:00 ET

Herborium Group, Inc. Enters the US Hispanic Market With Its Proprietary Acne Treatment AcnEase®, a Novel Herbal, Clinically Tested Acne Solution

SADDLE BROOK, NJ--(Marketwire - June 9, 2009) - Herborium Group, Inc. (PINKSHEETS: HBRM), a botanical therapeutics® company that develops, licenses and markets novel botanical ingredient based medicinal products, today announced that it has entered the US Hispanic market with its breakthrough acne treatment AcnEase®. The Hispanic market is the largest and most affluent consumer ethnic market in the American marketing landscape. Herborium has launched a multi-channel campaign to cover electronic (Internet), as well as targeted wholesale and brand-building channels for the Hispanic market, through its affiliation with Hispanic Trending, Inc., a specialty marketing company.

"We are very excited about the potential for AcnEase®, our novel, herbal acne treatment, in the Hispanic market," said Dr. Agnes P. Olszewski, CEO of Herborium Group. "AcnEase is a most suitable product for the Hispanic market, which has shown strong interest and growth in consumer spending on beauty and grooming products. In addition, AcnEase is the only over the counter acne treatment that has no discoloration effect on olive toned, or darker, complexion."

In clinical studies AcnEase® has demonstrated up to 95% efficacy in diminishing acne, and improving skin condition, for both Caucasian and non Caucasian skin types.

For more information about Herborium and AcnEase visit the following links: and

About Herborium Group, Inc.

Herborium Group, Inc., a botanical therapeutics® company, is focused on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for the Industry: "Botanical Drug Products (FDA Guidance 2004)" to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to Western markets. The company has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.

Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Sunrise Consulting Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.

Contact Information

  • Contact:
    Herborium Group, Inc.
    Dr. Agnes Olszewski
    201 647 3757